Barr in Catbird Seat As Razadyne Trial Begins; Pharma Backs Norvasc Review
Executive Summary
The pharma industry may soon feel the impact of the U.S. Supreme Court's expansion of what constitutes an obvious invention
You may also be interested in...
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements
Federal Circuit Denies En Banc Review of Norvasc Decision
The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious